Tubeimoside‑1 inhibits the proliferation and metastasis by promoting miR‑126‑5p expression in non‑small cell lung cancer cells

Shi,Hanbing; Bi,Hongxia; Sun,Xingyuan; Dong,Haiying; Jiang,Yunfei; Mu,Haijun; Li,Wei; Liu,Guohua; Gao,Ruizhi; Su,Jiang

doi:10.3892/ol.2018.9051

Tubeimoside‑1 inhibits the proliferation and metastasis by promoting miR‑126‑5p expression in non‑small cell lung cancer cells

Authors:
- Hanbing Shi
- Hongxia Bi
- Xingyuan Sun
- Haiying Dong
- Yunfei Jiang
- Haijun Mu
- Wei Li
- Guohua Liu
- Ruizhi Gao
- Jiang Su
View Affiliations

Affiliations: Department of Respiration II, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, Heilongjiang 161006, P.R. China, Department of Respiratory Medicine, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, Heilongjiang 161006, P.R. China, Department of Neurology, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, Heilongjiang 161006, P.R. China, Laboratory Center of Ultrastructural Pathology, Qiqihar Medical University, Qiqihar, Heilongjiang 161006, P.R. China
Published online on: June 29, 2018 https://doi.org/10.3892/ol.2018.9051
Pages: 3126-3134
Copyright: © Shi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tubeimoside‑1 (TBMS1) possesses broad anticancer activities, including the cytostatic and anti‑angiogenesis effects in lung cancer. However, the effect of TBMS1 on the metastasis of non‑small cell lung cancer (NSCLC) cells and the potential underlying mechanism remain unclear. In the present study, a cell counting kit‑8 assay revealed that TBMS1 suppressed the proliferation of NCI‑H1299 cells significantly, particularly following 48 h of treatment. Further studies showed that TBMS1 notably enhanced the apoptosis, and inhibited the migration and invasion of NCI‑H1299 cells upon treatment for 48 h. A total of 14 NSCLC tissues and 14 normal adjacent tissues were collected, reverse transcription‑ quantitative polymerase chain reaction revealed decreased expression of microRNA (miR)‑126‑5p in NSCLC tissues compared with adjacent NSCLC tissues, which was reversed following TBMS1 administration in NCI‑H1299 cells. The overexpression of miR‑126‑5p induced by TBMS1 was demonstrated to target and downregulate vascular endothelial growth factor (VEGF)‑A. Simultaneously, the expression of VEGF‑R2 was reduced notably, along with a significant declined in the phosphorylation levels of dual specificity mitogen‑activated protein kinase kinase 1 and extracellular signal‑regulated kinase (ERK)1/2. Overall, the aforementioned results indicated that TBMS1 inhibited the proliferation and metastasis, and promoted the apoptosis of NCI‑H1299 cells, which may be mediated by overexpressing miR‑126‑5p, which inactivates the VEGF‑A/VEGFR2/ERK signaling pathway. Therefore, TBMS1 may be a promising drug for prevention and treatment of NSCLC.

View Figures

View References

1	National Lung Screening Trial Research Team, . Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM and Sicks JD: Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 365:395–409. 2011. View Article : Google Scholar : PubMed/NCBI
2	Minguet J, Smith KH and Bramlage P: Targeted therapies for treatment of non-small cell lung cancer-Recent advances and future perspectives. Int J Cancer. 138:2549–2561. 2016. View Article : Google Scholar : PubMed/NCBI
3	Villaruz LC and Socinski MA: Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes. Eur J Cancer. 56:162–171. 2016. View Article : Google Scholar : PubMed/NCBI
4	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA A Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
5	Yin Y, Chen W, Tang C, Ding H, Jang J, Weng M, Cai Y and Zou G: NF-kB, JNK and p53 pathways are involved in tubeimoside-1-induced apoptosis in HepG2 cells with oxidative stress and G (2)/M cell cycle arrest. Food Chem Toxicol. 49:3046–3054. 2011. View Article : Google Scholar : PubMed/NCBI
6	Gu Y, Korbel C, Scheuer C, Nenicu A, Menger MD and Laschke MW: Tubeimoside-1 suppresses tumor angiogenesis by stimulation of proteasomal VEGFR2 and Tie2 degradation in a non-small cell lung cancer xenograft model. Oncotarget. 7:5258–5272. 2016.PubMed/NCBI
7	Bian Q, Liu P, Gu J and Song B: Tubeimoside-1 inhibits the growth and invasion of colorectal cancer cells through the Wnt/β-catenin signaling pathway. Int J Clin. 8:12517–12524. 2015.
8	Hao W, Wang S and Zhou Z: Tubeimoside-1 (TBMS1) inhibits lung cancer cell growth and induces cells apoptosis through activation of MAPK-JNK pathway. Int J Clin Exp Pathol. 8:12075–12083. 2015.PubMed/NCBI
9	Lin Y, Xie G, Xia J, Su D, Liu J, Jiang F and Xu Y: TBMS1 exerts its cytotoxicity in NCI-H460 lung cancer cells through nucleolar stress-induced p53/MDM2-dependent mechanism, a quantitative proteomics study. Biochim Biophys Acta. 1864:204–210. 2016. View Article : Google Scholar : PubMed/NCBI
10	Jia G, Wang Q, Wang R, Deng D, Xue L, Shao N, Zhang Y, Xia X, Zhi F and Yang Y: Tubeimoside-1 induces glioma apoptosis through regulation of Bax/Bcl-2 and the ROS/Cytochrome C/Caspase-3 pathway. Onco Targets Ther. 8:303–311. 2015.PubMed/NCBI
11	Zhang Y, Xu XM, Zhang M, Qu D, Niu HY, Bai X, Kan L and He P: Effects of tubeimoside-1 on the proliferation and apoptosis of BGC823 gastric cancer cells in vitro. Oncol Lett. 5:801–804. 2013. View Article : Google Scholar : PubMed/NCBI
12	Weng XY, Ma RD and Yu LJ: Apoptosis of human nasopharyngeal carcinoma CNE-2Z cells induced by tubeimoside I. Ai Zheng. 22:806–811. 2003.PubMed/NCBI
13	Peng Y, Zhong Y and Li G: Tubeimoside-1 suppresses breast cancer metastasis through downregulation of CXCR4 chemokine receptor expression. BMB Rep. 49:502–507. 2016. View Article : Google Scholar : PubMed/NCBI
14	Ni N, Zhang D, Xie Q, Chen J, Wang Z, Deng Y, Wen X, Zhu M, Ji J, Fan X, et al: Effects of let-7b and TLX on the proliferation and differentiation of retinal progenitor cells in vitro. Sci Rep. 4:66712014. View Article : Google Scholar : PubMed/NCBI
15	Lu M, Sun L, Zhou J, Zhao Y and Deng X: Dihydroartemi-sinin-induced apoptosis is associated with inhibition of sarco/endoplasmic reticulum calcium ATPase activity in colorectal cancer. Cell Biochem Biophys. 73:137–145. 2015. View Article : Google Scholar : PubMed/NCBI
16	Shan S, Lv Q, Zhao Y, Liu C, Sun Y, Xi K, Xiao J and Li C: Wnt/β-catenin pathway is required for epithelial to mesenchymal transition in CXCL12 over expressed breast cancer cells. Int J Clin Exp Pathol. 8:12357–12367. 2015.PubMed/NCBI
17	Ricciuti B, Mecca C, Crino L, Baglivo S, Cenci M and Metro G: Non-coding RNAs in lung cancer. Oncoscience. 1:674–705. 2014. View Article : Google Scholar : PubMed/NCBI
18	Singla AK, Downey CM, Bebb GD and Jirik FR: Characterization of a murine model of metastatic human non-small cell lung cancer and effect of CXCR4 inhibition on the growth of metastases. Oncoscience. 2:263–271. 2015. View Article : Google Scholar : PubMed/NCBI
19	Wu W, Bi C, Credille KM, Manro JR, Peek VL, Donoho GP, Yan L, Wijsman JA, Yan SB and Walgren RA: Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653, an inhibitor of several oncokinases, including MET. Clin Cancer Res. 19:5699–5710. 2013. View Article : Google Scholar : PubMed/NCBI
20	Meister J and Schmidt MH: miR-126 and miR-126*: New players in cancer. Sci World J. 10:2090–2100. 2010. View Article : Google Scholar
21	Shibayama Y, Kondo T, Ohya H, Fujisawa S, Teshima T and Iseki K: Upregulation of microRNA-126-5p is associated with drug resistance to cytarabine and poor prognosis in AML patients. Oncol Rep. 33:2176–2182. 2015. View Article : Google Scholar : PubMed/NCBI
22	Musiyenko A, Bitko V and Barik S: Ectopic expression of miR-126*, an intronic product of the vascular endothelial EGF-like 7 gene, regulates prostein translation and invasiveness of prostate cancer LNCaP cells. J Mol Med (Berl). 86:313–322. 2008. View Article : Google Scholar : PubMed/NCBI
23	Felli N, Felicetti F, Lustri AM, Errico MC, Bottero L, Cannistraci A, De Feo A, Petrini M, Pedini F, Biffoni M, et al: miR-126&126* restored expressions play a tumor suppressor role by directly regulating ADAM9 and MMP7 in melanoma. PLoS One. 8:e568242013. View Article : Google Scholar : PubMed/NCBI
24	Zhang Y, Yang P, Sun T, Li D, Xu X, Rui Y, Li C, Chong M, Ibrahim T, Mercatali L, et al: miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. Nat Cell Biol. 15:284–294. 2013. View Article : Google Scholar : PubMed/NCBI
25	Sanfiorenzo C, Ilie MI, Belaid A, Barlési F, Mouroux J, Marquette CH, Brest P and Hofman P: Two panels of plasma microRNAs as non-invasive biomarkers for prediction of recurrence in resectable NSCLC. PLoS One. 8:e545962013. View Article : Google Scholar : PubMed/NCBI
26	Vosa U, Vooder T, Kolde R, Vilo J, Metspalu A and Annilo T: Meta-analysis of microRNA expression in lung cancer. Int J Cancer. 132:2884–2893. 2013. View Article : Google Scholar : PubMed/NCBI
27	Yoshiji H, Gomez DE, Shibuya M and Thorgeirsson UP: Expression of vascular endothelial growth factor, its receptor and other angiogenic factors in human breast cancer. Cancer Res. 56:2013–2016. 1996.PubMed/NCBI
28	Volm M, Koomägi R and Mattern J: Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer. 74:64–68. 1997. View Article : Google Scholar : PubMed/NCBI
29	Hatva E, Kaipainen A, Mentula P, Jääskeläinen J, Paetau A, Haltia M and Alitalo K: Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors. Ame J Pathol. 146:368–378. 1995.
30	Ellis LM, Takahashi Y, Fenoglio CJ, Cleary KR, Bucana CD and Evans DB: Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma. Eur J Cancer. 34:337–340. 1998. View Article : Google Scholar : PubMed/NCBI
31	Boocock CA, Charnock-Jones DS, Sharkey AM, McLaren J, Barker PJ, Wright KA, Twentyman PR and Smith SK: Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natil Cancer Inst. 87:506–516. 1995. View Article : Google Scholar
32	Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF and Senger DR: Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol. 143:1255–1262. 1993.PubMed/NCBI
33	Ferrara N and Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev. 18:4–25. 1997. View Article : Google Scholar : PubMed/NCBI
34	Liu B, Peng XC, Zheng XL, Wang J and Qin YW: MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo. Lung Cancer. 66:169–175. 2009. View Article : Google Scholar : PubMed/NCBI
35	Tang R, Pei L, Bai T and Wang J: Down-regulation of microRNA-126-5p contributes to overexpression of VEGFA in lipopolysaccharide-induced acute lung injury. Biotechnol Lett. 38:1277–1284. 2016. View Article : Google Scholar : PubMed/NCBI
36	Matsumoto K and Ema M: Roles of VEGF-A signalling in development, regeneration and tumours. J Biochem. 156:1–10. 2014. View Article : Google Scholar : PubMed/NCBI
37	Zhang W and Liu HT: MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 12:9–18. 2002. View Article : Google Scholar : PubMed/NCBI
38	Santos SC and Dias S: Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood. 103:3883–3889. 2004. View Article : Google Scholar : PubMed/NCBI
39	Tian Y, Xie Q, Tian Y, Liu Y, Huang Z, Fan C, Hou B, Sun D, Yao K and Chen T: Radioactive ¹²⁵I seed inhibits the cell growth, migration and invasion of nasopharyngeal carcinoma by triggering DNA damage and inactivating VEGF-A/ERK signaling. PLoS One. 8:e740382013. View Article : Google Scholar : PubMed/NCBI